Comparing the biological activity and composition of Cerebrolysin with other peptide preparations.

Seidl LF, Aigner L

Journal of medicine and life1 Jan 2024Cited by 1 (Europe PMC)

PMID38737662PMCIDPMC11080511DOI10.25122/jml-2024-0129PepBankPUB-38737662

Summary

Neurological disorders, ranging from acute forms such as stroke and traumatic brain injury to neurodegenerative diseases like dementia, are the leading cause of disability-adjusted life years (DALYs) worldwide. A promising approach to address these conditions and promote nervous system regeneration is the use of the neuropeptide preparation Cerebrolysin, which has been shown to be effective in both clinical and preclinical studies. Despite claims of similar clinical efficacy and safety by several peptide preparations, concerns regarding their generic composition and efficacy have been previously raised. Based on these reports, we analyzed the peptide composition and neurotrophic activity of several peptide preparations allegedly similar to Cerebrolysin and approved in some countries for treating neurological diseases. Our results demonstrate that these preparations lack relevant biological activity and that the peptide composition is significantly different from Cerebrolysin. peptide.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

01LabNot a test of Cerebrolysin aloneOther designActivity measurement
In laboratory comparisons with Cerebrolysin, allegedly similar preparations lacked relevant biological activity.
In plain wordsIn lab tests, preparations compared with Cerebrolysin lacked relevant biological activity.
Peptide
Cerebrolysin
Outcome
Direction not reportedBiological activity comparison
Study
n: not reported in source
Comparator
Other peptide preparations
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Our results demonstrate that these preparations lack relevant biological activity and that the peptide composition is significantly different from Cerebrolysin. peptide.
1 context sentence(design, population, supporting numbers)
Summary · context
Based on these reports, we analyzed the peptide composition and neurotrophic activity of several peptide preparations allegedly similar to Cerebrolysin and approved in some countries for treating neurological diseases.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3873766201
02LabNot a test of Cerebrolysin aloneOther designOther
In laboratory analysis, peptide compositions of allegedly similar preparations differed significantly from Cerebrolysin.
In plain wordsIn lab tests, other preparations had peptide compositions that differed significantly from Cerebrolysin.
Peptide
Cerebrolysin
Outcome
Not applicablePeptide composition
Study
n: not reported in source
Comparator
Other peptide preparations
Outcome group
Product quality and purity · Pharmacology
Source sentences
Summary
Our results demonstrate that these preparations lack relevant biological activity and that the peptide composition is significantly different from Cerebrolysin. peptide.
1 context sentence(design, population, supporting numbers)
Summary · context
Based on these reports, we analyzed the peptide composition and neurotrophic activity of several peptide preparations allegedly similar to Cerebrolysin and approved in some countries for treating neurological diseases.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3873766202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

Enrolling by invitationNot applicableNCT06677502

Cerebrolysin in Critically Ill Patients With Delirium

Medical University of Lublinn = 5001 Jan 2024 to est. 31 Dec 2025

Cognitive Impairment

Trial page ClinicalTrials.govUpdated 31 Dec 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.